Skip to main content
SpringerLink
Log in

Biomarkers for Renal Cell Carcinoma

  • Chapter
  • First Online:
Kidney Cancer

Abstract

In recent years, there has been a remarkable increase in interest in biomarkers, especially as a tool with tremendous utility in cancer. Biomarkers provide opportunities for early detection, accurate diagnosis, and predicting clinical outcome with regard to response to therapy, potential tumor recurrence, and survival, and they provide additional insights into the pathogenesis of disease. Biomarkers also provide both a strategy for clustering “like” subsets of tumors on a population level, and also allow individualized tumor information for case-by-case decision-making. Biomarkers are especially attractive because they are quantitative, objective, and readily adaptable for clinical implementation. Traditional clinical practice relies heavily on signs and symptoms as well as radiographic imagery, which can be highly subjective as well as influenced by a variety of sources independent of the cancer. In contrast, biomarkers are helpful as more objective and reliable factors, which can either supplement or replace these largely subjective measures. Moreover, biomarkers can potentially play important roles in clinical research by clarifying measurable endpoints, which may lead to significant decrease of cost and duration of clinical trials. Currently, research institutes, pharmaceutical companies, and the United States Food and Drug Administration (FDA) are putting vigorous effort toward integrating biomarkers more extensively into clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845–856

    PubMed  CAS  Google Scholar 

  2. Linehan WM, Rini BI, Yang JC (2008) Cancer of the kidney. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 8th edn. Lippincott William & Wilkins, Philadelphia, pp 1331–1354

    Google Scholar 

  3. Lin L, Huang Z, Gao Y et al (2011) LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J Proteome Res 10(3):1396–1405

    PubMed  CAS  Google Scholar 

  4. Seliger B, Jasinski S, Dressler SP et al (2011) Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? J Proteome Res 10(1):191–199

    PubMed  CAS  Google Scholar 

  5. Nickerson ML, Jaeger E, Shi Y et al (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14(15):4726–4734

    PubMed  CAS  Google Scholar 

  6. Kaelin WG Jr (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865–873

    PubMed  CAS  Google Scholar 

  7. Gordan JD, Lal P, Dondeti VR et al (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6):435–446

    PubMed  CAS  Google Scholar 

  8. Li M, Kim WY (2011) Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med 15(2):187–196

    PubMed  CAS  Google Scholar 

  9. Semenza GL (2001) HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13(2):167–171

    PubMed  CAS  Google Scholar 

  10. Sang N, Fang J, Srinivas V et al (2002) Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22(9):2984–2992

    PubMed  CAS  Google Scholar 

  11. Maynard MA, Qi H, Chung J et al (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278(13):11032–11040

    PubMed  CAS  Google Scholar 

  12. Raval RR, Lau KW, Tran MG et al (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25(13):5675–5686

    PubMed  CAS  Google Scholar 

  13. Rathmell WK, Acs G, Simon MC et al (2004) HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res 24(1):167–169

    PubMed  CAS  Google Scholar 

  14. Hacker KE, Lee CM, Rathmell WK (2008) VHL type 2B mutations retain VBC complex form and function. PLoS One 3(11):e3801

    PubMed  Google Scholar 

  15. Iliopoulos O, Levy AP, Jiang C et al (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93(20):10595–10599

    PubMed  CAS  Google Scholar 

  16. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732

    PubMed  CAS  Google Scholar 

  17. Fox SB, Turley H, Cheale M et al (2004) Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol 202(3):313–320

    PubMed  CAS  Google Scholar 

  18. Calvani M, Trisciuoglio D, Bergamaschi C et al (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 68(1):285–291

    PubMed  CAS  Google Scholar 

  19. Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143

    PubMed  CAS  Google Scholar 

  20. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    PubMed  CAS  Google Scholar 

  21. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    PubMed  CAS  Google Scholar 

  22. Ivanov S, Liao SY, Ivanova A et al (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158(3):905–919

    PubMed  CAS  Google Scholar 

  23. Genega EM, Ghebremichael M, Najarian R et al (2010) Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 134(6):873–879

    PubMed  CAS  Google Scholar 

  24. Pantuck AJ, Fang Z, Liu X et al (2005) Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol 23(16 Suppl Pt 1):abstract 4535

    Google Scholar 

  25. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281

    PubMed  CAS  Google Scholar 

  26. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372(9637):449–456

    PubMed  CAS  Google Scholar 

  27. Bluemke K, Bilkenroth U, Meye A et al (2009) Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev 18(8):2190–2194

    PubMed  CAS  Google Scholar 

  28. Slaby O, Jancovicova J, Lakomy R et al (2010) Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29:90

    PubMed  Google Scholar 

  29. Wood SL, Rogers M, Cairns DA et al (2010) Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 103(1):101–111

    PubMed  CAS  Google Scholar 

  30. Dolley-Hitze T, Jouan F, Martin B et al (2010) Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 103(11):1698–1705

    PubMed  CAS  Google Scholar 

  31. Klatte T, Seligson DB, Riggs SB et al (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13(24):7388–7393

    PubMed  CAS  Google Scholar 

  32. Jagdev SP, Gregory W, Vasudev NS et al (2010) Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 103(11):1649–1656

    PubMed  CAS  Google Scholar 

  33. D’Alterio C, Consales C, Polimeno M et al (2010) Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets 10(7):772–781

    PubMed  Google Scholar 

  34. Vasudev NS, Sim S, Cairns DA et al (2009) Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer 101(7):1175–1182

    PubMed  CAS  Google Scholar 

  35. Wagener N, Macher-Goeppinger S, Pritsch M et al (2010) Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10:524

    PubMed  Google Scholar 

  36. Mosashvilli D, Kahl P, Mertens C et al (2010) Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci 101(12):2664–2669

    PubMed  CAS  Google Scholar 

  37. Ronkainen H, Vaarala MH, Hirvikoski P et al (2010) HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol 32(3):481–487

    PubMed  Google Scholar 

  38. Hoffmann NE, Sheinin Y, Lohse CM et al (2008) External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 112(7):1471–1479

    PubMed  Google Scholar 

  39. Kawata N, Nagane Y, Hirakata H et al (2007) Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 69(6):1049–1053

    PubMed  Google Scholar 

  40. Merseburger AS, Hennenlotter J, Kuehs U et al (2008) Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int 80(4):372–377

    PubMed  CAS  Google Scholar 

  41. Abou Youssif T, Fahmy MA, Koumakpayi IH et al (2011) The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117(2):290–300

    PubMed  CAS  Google Scholar 

  42. Zubac DP, Wentzel-Larsen T, Seidal T et al (2010) Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol 10:20

    PubMed  Google Scholar 

  43. Bandiera A, Melloni G, Freschi M et al (2009) Prognostic factors and analysis of S100a4 protein in resected pulmonary metastases from renal cell carcinoma. World J Surg 33(7):1414–1420

    PubMed  Google Scholar 

  44. Pena C, Lathia C, Shan M et al (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16(19):4853–4863

    PubMed  CAS  Google Scholar 

  45. Zubac DP, Bostad L, Kihl B et al (2009) The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol 182(5):2144–2149

    PubMed  Google Scholar 

  46. Cindolo L, Chiodini P, Gallo C et al (2008) Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 113(1):65–71

    PubMed  Google Scholar 

  47. Motzer RJ, Bukowski RM, Figlin RA et al (2008) Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113(7):1552–1558

    PubMed  CAS  Google Scholar 

  48. Leibovich BC, Lohse CM, Crispen PL et al (2010) Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183(4):1309–1315

    PubMed  Google Scholar 

  49. Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400

    PubMed  Google Scholar 

  50. Katz MD, Serrano MF, Humphrey PA et al (2009) The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urol Oncol [Epub ahead of print]

    Google Scholar 

  51. Molina AM, Tickoo SK, Ishill N et al (2010) Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol [Epub ahead of print]

    Google Scholar 

  52. Furge KA, Lucas KA, Takahashi M et al (2004) Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 64(12):4117–4121

    PubMed  CAS  Google Scholar 

  53. Meloni-Ehrig AM (2002) Renal cancer: cytogenetic and molecular genetic aspects. Am J Med Genet 115(3):164–172

    PubMed  Google Scholar 

  54. Sultmann H, von Heydebreck A, Huber W et al (2005) Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11(2 Pt 1):646–655

    PubMed  Google Scholar 

  55. Klatte T, Rao PN, de Martino M et al (2009) Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 27(5):746–753

    PubMed  Google Scholar 

  56. Balint I, Szponar A, Jauch A et al (2009) Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype. J Clin Pathol 62(10):892–895

    PubMed  CAS  Google Scholar 

  57. Kovacs G, Fuzesi L, Emanual A et al (1991) Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 3(4):249–255

    PubMed  CAS  Google Scholar 

  58. Speicher MR, Schoell B, du Manoir S et al (1994) Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 145(2):356–364

    PubMed  CAS  Google Scholar 

  59. Dalgliesh GL, Furge K, Greenman C et al (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279):360–363

    PubMed  CAS  Google Scholar 

  60. Takahashi M, Rhodes DR, Furge KA et al (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98(17):9754–9759

    PubMed  CAS  Google Scholar 

  61. Brannon AR, Reddy A, Seiler M et al (2010) Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1(2):152–163

    PubMed  CAS  Google Scholar 

  62. Rini BI, Zhou M, Aydin H et al (2010) Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). J Clin Oncol 28(15 Suppl):abstract 4501

    Google Scholar 

  63. Cifola I, Spinelli R, Beltrame L et al (2008) Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 7:6

    PubMed  Google Scholar 

  64. Costa VL, Henrique R, Ribeiro FR et al (2007) Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7:133

    PubMed  Google Scholar 

  65. Beroukhim R, Brunet JP, Di Napoli A et al (2009) Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69(11):4674–4681

    PubMed  CAS  Google Scholar 

  66. Vieira J, Henrique R, Ribeiro FR et al (2010) Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer 49(10):935–947

    PubMed  CAS  Google Scholar 

  67. Kleinrath T, Gassner C, Lackner P et al (2007) Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25(7):845–851

    PubMed  CAS  Google Scholar 

  68. Kawai Y, Sakano S, Korenaga Y et al (2007) Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52(4):1147–1155

    PubMed  CAS  Google Scholar 

  69. Upton MP, Parker RA, Youmans A et al (2005) Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28(5):488–495

    PubMed  CAS  Google Scholar 

  70. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9(2):802–811

    PubMed  CAS  Google Scholar 

  71. DePrimo SE, Bello C (2007) Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 18(Suppl 10):11–19

    Google Scholar 

  72. Porta C, Paglino C, De Amici M et al (2010) Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77(9):809–815

    PubMed  CAS  Google Scholar 

  73. Tsimafeyeu I, Demidov L, Ta H et al (2010) Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol (Meeting Abstr) 28(15 Suppl):4621

    Google Scholar 

  74. Patel PH, Chadalavada RS, Ishill NM et al (2008) Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol (26):abstract 5008

    Google Scholar 

  75. Perez-Gracia JL, Prior C, Guillen-Grima F et al (2009) Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 101(11):1876–1883

    PubMed  CAS  Google Scholar 

  76. Choueiri TK, Vaziri SA, Jaeger E et al (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180(3):860–865; discussion 865–866

    PubMed  CAS  Google Scholar 

  77. Bukowski RM, Eisen T, Szczylik C et al (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol (25):abstract 5023

    Google Scholar 

  78. Busse A, Asemissen A, Nonnenmacher A et al (2011) Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-beta1 mRNA expression in peripheral blood mononuclear cells. J Immunother 34(1):113–119

    PubMed  CAS  Google Scholar 

  79. Heymach J, Tran HT, Fritsche HA et al (2009) Lower baseline levels of plasma hepatocyte growth factor (HGF), IL-6, IL-8 are correlated with tumor shrinkage in renal cell carcinoma patients treated with pazopanib. Presented at the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics (abstract A11)

    Google Scholar 

  80. Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25(29):4536–4541

    PubMed  CAS  Google Scholar 

  81. Dutcher JP, de Souza P, McDermott D et al (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202–209

    PubMed  CAS  Google Scholar 

  82. Armstrong AJ, George DJ, Halabi S et al (2010) Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstr) 28(15 Suppl):4631

    Google Scholar 

  83. Atkins M, Regan M, McDermott D et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11(10):3714–3721

    PubMed  CAS  Google Scholar 

  84. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265

    PubMed  CAS  Google Scholar 

  85. Cangiano T, Liao J, Naitoh J et al (1999) Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17(2):523–528

    PubMed  CAS  Google Scholar 

  86. Motzer RJ, Bacik J, Mariani T et al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20(9):2376–2381

    PubMed  Google Scholar 

  87. Jaeger E, Waldman F, Roydasgupta R et al (2008) Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between interleukin-2 complete and non-responders. J Clin Oncol 26(15 Suppl):abstract 5043

    Google Scholar 

  88. Ito N, Eto M, Nakamura E et al (2007) STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 25(19):2785–2791

    PubMed  CAS  Google Scholar 

  89. Rini BI (2010) Biomarkers: hypertension following anti-angiogenesis therapy. Clin Adv Hematol Oncol 8(6):415–416

    PubMed  Google Scholar 

  90. Rini BI, Garcia JA, Cooney MM et al (2010) Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 28(17):e284–e285; author reply e286–e287

    PubMed  Google Scholar 

  91. Rini BI, Cohen DP, Lu D et al (2010) Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at the 2010 genitourinary cancers symposium (abstract 312)

    Google Scholar 

  92. Gad S, Sultan-Amar V, Meric J et al (2007) Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Target Oncol 2:3–6

    Google Scholar 

  93. Hutson T, Davis ID, Macheils JH et al (2008) Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J Clin Oncol (26):abstract 5046

    Google Scholar 

  94. Deprimo SE, Bello CL, Smeraglia J et al (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32

    PubMed  Google Scholar 

  95. Rini BI, Michaelson MD, Rosenberg JE et al (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26(22):3743–3748

    PubMed  CAS  Google Scholar 

  96. Plantade A, Choueiri B, Escudier B et al (2007) Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol 25(18 Suppl):abstract 5037

    Google Scholar 

  97. Velickovic M, Delahunt B, McIver B et al (2002) Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 15(5):479–485

    PubMed  Google Scholar 

  98. Pantuck AJ, Seligson DB, Klatte T et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109(11):2257–2267

    PubMed  CAS  Google Scholar 

  99. Youssif TA, Fahmy MA, Koumakpayi IH et al (2010) The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117(2):290–300

    PubMed  Google Scholar 

  100. Figlin RA, de Souza P, McDermott D et al (2009) Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 115(16):3651–3660

    PubMed  CAS  Google Scholar 

  101. Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17(6):596–603

    PubMed  CAS  Google Scholar 

  102. Cho D, Signoretti S, Dabora S et al (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5(6):379–385

    PubMed  CAS  Google Scholar 

  103. Xu G, Xiang CQ, Lu Y et al (2009) Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma. Cancer Lett 282(2):205–213

    PubMed  CAS  Google Scholar 

  104. Seliger B, Dressler SP, Wang E et al (2009) Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics 9(6):1567–1581

    PubMed  CAS  Google Scholar 

  105. Catchpole G, Platzer A, Weikert C et al (2011) Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med 15(1):109–118

    PubMed  CAS  Google Scholar 

  106. Kim K, Aronov P, Zakharkin SO et al (2009) Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8(3):558–570

    PubMed  CAS  Google Scholar 

  107. Zira AN, Theocharis SE, Mitropoulos D et al (2010) (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J Proteome Res 9(8):4038–4044

    PubMed  CAS  Google Scholar 

  108. Heinzelmann J, Henning B, Sanjmyatav J et al (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29(3):367–373

    PubMed  CAS  Google Scholar 

  109. Liu H, Brannon AR, Reddy AR et al (2010) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 4:51

    PubMed  Google Scholar 

  110. Minamimoto R, Nakaigawa N, Tateishi U et al (2011) Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med 35(12):918–923

    Google Scholar 

  111. Divgi CR, Pandit-Taskar N, Jungbluth AA et al (2007) Preoperative characterization of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8(4):304–310

    PubMed  CAS  Google Scholar 

  112. Spero M, Brkljacic B, Kolaric B et al (2010) Preoperative staging of renal cell carcinoma using magnetic resonance imaging: comparison with pathological staging. Clin Imaging 34(6):441–447

    PubMed  Google Scholar 

  113. Wang H, Cheng L, Zhang X et al (2010) Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology 257(1):135–143

    PubMed  Google Scholar 

  114. Hillman GG, Singh-Gupta V, Al-Bashir AK et al (2010) Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol 3(5):293–306

    PubMed  Google Scholar 

  115. Pedrosa I, Alsop DC, Rofsky NM (2009) Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 115(10 Suppl):2334–2345

    PubMed  Google Scholar 

  116. Katz-Brull R, Rofsky NM, Morrin MM et al (2005) Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol 288(4):F637–F641

    PubMed  CAS  Google Scholar 

  117. Lassau N, Chebil M, Chami L et al (2010) Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target Oncol 5(1):53–58

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine and Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Dr., Chapel Hill, 27599, NC, USA

    Mingqing Li & W. Kimryn Rathmell

Authors
  1. Mingqing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Kimryn Rathmell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Kimryn Rathmell .

Editor information

Editors and Affiliations

  1. , Dept. of Internal Medicine, Division of, University of California School of Medic, X Street 4501, Sacramento, 95817, California, USA

    Primo N. Lara, Jr.

  2. , Department of Genitourinary Medical Onco, University of Texas MD Anderson Cancer C, Holcombe Blvd 1515, Houston, 77030, Texas, USA

    Eric Jonasch

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Li, M., Rathmell, W.K. (2012). Biomarkers for Renal Cell Carcinoma. In: Lara, Jr., P., Jonasch, E. (eds) Kidney Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21858-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21858-3_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21857-6

  • Online ISBN: 978-3-642-21858-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation